April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
COMBI-i Regimen Does Not Improve PFS in Unresectable or Metastatic BRAF V600E-Mutant Melanoma
August 24th 2020Progression-free survival was not improved with the combination of spartalizumab, dabrafenib, and trametinib when administered as treatment of untreated patients with unresectable or metastatic BRAF V600E-mutant cutaneous melanoma compared with dabrafenib plus trametinib alone, missing the primary end point of the phase 3 COMBI-I clinical trial.
Read More
Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies
July 26th 2020A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.
Read More
Pembrolizumab Shows Long-Term Benefit in Advanced Melanoma Subgroups
July 17th 2020A retrospective 10-year analysis of 3 randomized clinical trials explored the question of whether BRAF V600E/K mutations or previous use of a BRAF inhibitor with or without a MEK inhibitor in patients with metastatic disease impacted patient response to pembrolizumab.
Read More
Cemiplimab Upholds Efficacy in 3-Year Follow-up for Advanced Cutaneous Squamous Cell Carcinoma
July 1st 2020In an interview with Targeted Oncology, Danny Rischin, MD, director, discussed the findings from the EMPOWER-CSCC-1 study of cemiplimab in advanced cutaneous squamous cell carcinoma that led to the drug’s FDA approval.
Read More
Fast Track Designation Granted to Seviprotimut-L Vaccine for Adjuvant Use in Stage IIB/IIC Melanoma
June 23rd 2020With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,
Read More
Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
May 31st 2020“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”
Read More
Combination Regimens Inspire Hope for the Treatment of Melanoma
May 4th 2020In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.
Read More
Exposure to ruxolitinib, hydroxyurea, and pipobroman as first-line treatment of Philadelphia-negative myeloproliferative neoplasms alone or in combination with other cytoreductive treatment may increase the probability of patients developing non-melanoma skin cancer, highlighting a need for active dermatological surveillance of these patients, according to findings from the MPN-K study, published in Leukemia.
Read More
Novel Intralesional Injection Achieves Complete Histological Clearance in Squamous Cell Carcinoma
April 10th 2020Treatment with <a>STP705</a> led to the achievement of complete histological clearance of squamous cell carcinoma <em>in situ</em> in a large proportion of patients, meeting the primary end point of the study, according to an interim analysis of the first 3 cohorts in an ongoing phase II clinical trial in patients with non-melanoma skin cancer announced by Sirnaomics Inc.
Read More
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 7th 2020The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Read More
Rarity of Uveal Melanoma Challenges Clinical Trial Enrollment
April 4th 2020In an interview with Targeted Oncology, Richard D. Carvajal, MD, discussed the challenges of conducting clinical trials for the treatment of patients with uveal melanoma, as well as the excitement surrounding 2 potential therapies in this space.
Read More
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30th 2020An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
Read More
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
March 30th 2020A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Read More
Targeted Therapies Contribute to Significant Decline in Melanoma-Related Mortality
March 24th 2020The mortality rate for cutaneous melanoma was significantly reduced between 2013 to 2016 as a result of new targeted therapies for metastatic disease, according to a recent report in the American Journal of Public Health. It is the largest death decline ever recorded for skin cancer.
Read More
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23rd 2020In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Read More
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21st 2020Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Read More
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20th 2020Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Read More
Adjuvant Ipilimumab Dose Improves Survival Benefit for Resected High-Risk Melanoma
March 17th 2020Adjuvant ipilimumab at a dose of 3 mg/kg demonstrated a survival benefit in patients with resected high-risk melanoma compared with high-dose interferon alfa-2b, according to the findings for a phase III E1609 clinical trial from the North American Intergroup.
Read More